Clinical trials: New Onset Diabetes After Transplant
Diabetes Mellitus, Adult-Onset
Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation
New onset diabetes after renal transplantation (NODAT) is a common and severe complication negatively influencing graft and patient survival. Cyclosporine (CsA) and Tacrolimus are the basis of modern immunosuppression.
- Trial name
- 01-DMPT (NCT01002339)
- Testing
- Tacrolimus with rapid steroid withdrawal, Tacrolimus with steroids minimization, CsA with steroid minimization
- Where
- 10 sites in Spain
- Volunteers
- 134 people
- Sponsor
- Armando Torres Ramírez
Acute Graft Rejection, Diabetes
A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf
While the incidence of acute rejection and early graft loss have improved dramatically with the advent of newer immunosuppressant medications, improvements in long-term patient and allograft survival after kidney transplantation…
- Trial name
- Astellas (NCT01265537)
- Testing
- Tacrolimus
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
Type 2 Diabetes, End Stage Renal Disease
Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation
This study is designed to see if the use of the drug Sitagliptin (used to reduce insulin resistance) will delay or prevent kidney transplant patients from getting diabetes.
- Trial name
- NCT00936663
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Nebraska
Posttransplant Diabetes Mellitus
Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant
The purpose of this study is to determine whether sitagliptin is effective in preventing the development of new-onset diabetes after kidney transplant (NODAT).
- Trial name
- NCT01928199
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Washington University School of Medicine
Acute Cellular Graft Rejection, New Onset Diabetes After Transplant
Budesonide for Liver Transplant Immune Suppression
This is a pilot study that investigates the efficacy and safety of budesonide as an immune suppressing agent for liver transplant recipients in the early post-transplant period.
- Trial name
- NCT03304626
- Testing
- Budesonide 3Mg Capsule, Standard of Care Prednisone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Prevention of New Onset Diabetes Among Kidney Transplant Patients
A Clinical Trial to Prevent New Onset Diabetes After Transplantation
Specific Aim 1: To determine the clinical efficacy of early initiation of insulin therapy in decreasing the incidence of NODAT among de novo kidney transplant patients with manifested post-transplant hyperglycemia during the…
- Trial name
- ITP-NODAT (NCT01683331)
- Testing
- Insulin treatment for hyperglycemia
- Where
- United States
- Volunteers
- 251 people
- Sponsor
- University of Michigan
Diabetes Mellitus
Comparison of Insulin Therapy in Treating Post-Transplant Diabetes
To determine if the use of insulin isophane results in improved control of blood sugars compared to the use of insulin glargine in new onset diabetes after kidney, lung, or heart transplantation (NODAT).
- Trial name
- NCT01963728
- Testing
- Insulin, Isophane, insulin glargine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Inova Health Care Services